Etid klinik pou Leukemi nan Ohio
26 etid pou Leukemi ap chèche patisipan nan sit nan Ohio.
Vil nan Ohio
Tèks ofisyèl etid la (Anglè)
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 8, Columbus
Ap rekriteFaz 3
Laj 18 a 71 · Tout sèks · Mizajou Sep 23, 2026 · NCT07504458A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Ohio State University, Columbus
Ap rekriteFaz 1/2
30 Days · Tout sèks · Mizajou Sep 16, 2026 · NCT04065399Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Cleveland
Ap rekriteFaz 3
Laj 18 a 18 · Tout sèks · Mizajou Sep 8, 2026 · NCT07509151Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Cinn Children Hosp Medical Center, Cincinnati
Ap rekriteFaz 2
Laj 1 a 18 · Tout sèks · Mizajou Sep 2, 2026 · NCT07354074Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07249346First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT07586618Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- UH Seidman Cancer Center, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Ohio State University, Columbus
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07007312Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteFaz 2
Laj 7 a 25 · Tout sèks · Mizajou Aug 19, 2026 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579Hairy Cell Leukemia Patient Data Registry
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT02560883Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT05475925Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteEtid obsèvasyon
Laj 0 a 38 · Tout sèks · Mizajou Jun 4, 2026 · NCT06131801Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 18, 2026 · NCT01790152A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT04256317The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
Ap rekriteFaz 1/2
Laj 12 a 95 · Tout sèks · Mizajou Apr 15, 2026 · NCT04329728Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT07356245Shwachman Diamond Syndrome Registry and Study
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Apr 6, 2026 · NCT06056908A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic Taussig Cancer Institute, Cleveland
- The James Cancer Hospital and Solove Research Institute, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT05735184Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteFaz 1
Laj 1 a 39 · Tout sèks · Mizajou Feb 18, 2026 · NCT03826992cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Cleveland Clinic, Cleveland
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Gabrail Cancer Research Center, Canton
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 31, 2025 · NCT06549790SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT06501196Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Cincinnati, Cincinnati
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 15, 2024 · NCT06034275Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.